Clinical data | |
---|---|
Trade names | Midamor, others |
Other names | MK-870 |
AHFS/Drugs.com | Monograph |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Readily absorbed, 15–25% |
Protein binding | ~23% |
Metabolism | Nil |
Onset of action | 2 hours (peak at 6–10 hours, duration ~24 hours) |
Elimination half-life | 6 to 9 hours |
Excretion | urine (20–50%), feces (40%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.018.205 |
Chemical and physical data | |
Formula | C6H8ClN7O |
Molar mass | 229.63 g·mol−1 |
3D model (JSmol) | |
Melting point | 240.5 to 241.5 °C (464.9 to 466.7 °F) |
| |
| |
(verify) |
Amiloride, sold under the trade name Midamor among others, is a medication typically used with other medications to treat high blood pressure or swelling due to heart failure or cirrhosis of the liver.[1][2] Amiloride is classified as a potassium-sparing diuretic. Amiloride is often used together with another diuretic, such as a thiazide or loop diuretic.[2] It is taken by mouth.[1] Onset of action is about two hours and it lasts for about a day.[2]
Common side effects include high blood potassium, vomiting, loss of appetite, rash, and headache.[1] The risk of high blood potassium is greater in those with kidney problems, diabetes, and those who are older.[1] Amiloride blocks the epithelial sodium channel (ENaC) in the late distal tubule, connecting tubule, and collecting duct of the nephron,[3] which both reduces absorption of sodium ion from the lumen of the nephron and reduces excretion of potassium ion into the lumen.[2]
Amiloride was developed in 1967.[4] It is on the World Health Organization's List of Essential Medicines.[5]